What Does the Research Say About Artemisinin and Cancer?

Interest in artemisinin has grown as researchers continue to study its potential relevance to cancer. However, the available evidence remains limited, making it important to understand the findings, research limitations, and safety concerns without assuming clinical benefit.

This blog examines what current studies suggest about artemisinin, the limitations of existing research, and the key safety considerations patients should understand when discussing integrative cancer support with their healthcare team.

Disclaimer: This content is for informational purposes only and does not replace medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making health decisions.

Medically reviewed by Imran Khan, MD, ABIM, IFMCP | Last medically reviewed: [Month Day, Year]

A person discussing environmental wellness and mold illness treatment with a functional medicine provider.

What Is Artemisinin?

According to the World Health Organization, artemisinin is derived from Artemisia annua, commonly known as sweet wormwood.[1] Its distinctive endoperoxide structure plays a central role in its biological activity and has led researchers to investigate how it interacts with iron or heme in different cellular environments.

Artemisinin is well established in malaria research and has also gained attention in early cancer studies. However, most cancer-related findings remain preclinical, and artemisinin is not FDA-approved as a cancer treatment. Many clinical studies focus on artesunate, so distinguishing it from artemisinin helps clarify the findings.

Artemisinin vs. Artesunate: What Is the Difference?

Although they are related, artemisinin and artesunate are not interchangeable:

  • Artemisinin is the original plant-derived compound and is commonly available in over-the-counter supplements. Product quality, absorption, and dosage may vary.
  • Artesunate is a water-soluble, semisynthetic derivative of artemisinin. Artesunate has been studied in oral and intravenous formulations, including in limited early-phase cancer research.

In the United States, FDA-approved Artesunate for Injection is specifically indicated for the initial treatment of severe malaria. Oral artesunate and the use of artesunate for cancer are not FDA-approved indications.[2]

What Current Artemisinin Research Shows

Laboratory and Animal Findings

Laboratory and animal studies suggest artemisinin derivatives may interact with iron or heme, activating their endoperoxide structure and producing reactive oxygen species. Researchers have observed oxidative stress, mitochondrial dysfunction, apoptosis, ferroptosis, and changes in pathways involved in tumor growth and blood vessel formation.[3] However, these findings do not confirm safe or effective cancer treatment in humans.

Early Clinical Findings

Human research remains limited and has primarily examined pharmaceutical-grade artesunate, often alongside conventional care. Small early-phase studies have focused on safety, dosing, tolerability, and short-term outcomes.[4] Larger controlled trials are needed to determine whether these compounds improve tumor response, disease progression, survival, or quality of life.

Understanding Test Results and Artemisinin Safety

Laboratory sensitivity testing may measure how sampled cancer cells respond to a substance under controlled laboratory conditions. These results do not establish that the same response will occur in a patient and should not be used independently to determine cancer treatment, dosing, or expected outcomes. Any findings should be interpreted alongside established clinical evidence, pathology, imaging, medical history, and guidance from the patient's oncology team.

Potential Safety Concerns

Safety data for artemisinin used outside approved antimalarial regimens are limited, especially for prolonged use in cancer settings. Safety findings also differ between artemisinin supplements and pharmaceutical artesunate, so adverse effects reported for one formulation should not automatically be assumed to apply identically to another.

Reported or theoretical concerns may include:

  • Gastrointestinal symptoms
  • Dizziness or fatigue
  • Liver-related abnormalities
  • Blood-related abnormalities, including hemolysis reported with pharmaceutical artesunate
  • Hypersensitivity reactions
  • Uncertain risks with prolonged or high-dose use
  • Variable supplement quality and potency

Medication and Supplement Interactions

Human data on interactions between artemisinin compounds and cancer treatments remain limited. Because potential interactions can vary by compound, formulation, dose, and other medications being used, patients should have their complete medication and supplement list reviewed by their oncology team before considering artemisinin or an artemisinin derivative. Combining artemisinin compounds with other supplements as part of a self-directed cancer regimen is not an established evidence-based treatment approach.

Questions About Artemisinin Research?

If you are considering artemisinin or another emerging approach, our team can help you understand the current evidence, limitations, potential risks, and how it may relate to your existing cancer care.

Schedule an Integrative Consultation

A Responsible Integrative Oncology Approach

Integrative oncology should complement evidence-based cancer care and never replace surgery, chemotherapy, radiation, immunotherapy, targeted therapy, or hormone therapy.

Before discussing any experimental substance, we evaluate:

  • Cancer type, stage, and current treatment plan
  • Medications and supplements already in use
  • Liver, kidney, and bone marrow function
  • Available labs and imaging
  • Potential treatment interactions
  • Quality-of-life and symptom priorities
  • Coordination with the patient's oncologist

There is no established artemisinin dose for prostate cancer or any other cancer. Online protocols, malaria dosing, supplement labels, and lab sensitivity results are not valid ways to determine a cancer regimen.

Disclaimer: Artemisinin and its derivatives are not established as safe or effective treatments for cancer. Do not start artemisinin or another supplement, determine a cancer dose, or change prescribed oncology treatment without discussing it with your oncology team or another qualified healthcare professional.

Frequently Asked Questions

No. Current clinical evidence does not show that artemisinin cures cancer. Most findings come from laboratory and animal studies, while human research remains preliminary.

Artemisinin compounds have affected cancer cells in some laboratory experiments. These findings do not demonstrate that artemisinin can safely or effectively treat tumors in people.

No evidence-based artemisinin dose for prostate cancer has been established. Artemisinin is not an approved prostate cancer treatment, and self-directed dosing may be unsafe.

No. Artesunate is a derivative of artemisinin with different pharmaceutical properties. Most limited human cancer research has evaluated controlled artesunate formulations rather than over-the-counter artemisinin supplements.

Reliable human interaction data are limited, so patients should not add artemisinin to chemotherapy or other cancer treatments without review by their oncology team.

Get Personalized Guidance From Our Integrative Care Team

Have questions about artemisinin or other emerging approaches? Dr. Khan and the IHAWMD team can help you understand the available research, its limitations, and how it relates to your current cancer care.

Schedule a consultation to discuss how personalized integrative support may complement your existing oncology plan.

Relevant Studies and References